Anthropic buys a one-person biotech and reports 17 lab-validated scorpion-toxin binders designed by Claude

On Oct. 27, Anthropic disclosed that it had bought Mithril Medicine in July. Mithril is a Cambridge, Massachusetts, company with one full-time employee (Becker's). Its founder, Cody Tranbarger, used Claude to manage contracts, logistics and experiments across part-time consultants and 11 outside laboratories. In under 18 months he moved a muscular dystrophy drug candidate from initial concept to promising results in mice (R&D World, AI ML Big Data). Mithril's programs for two rare muscular dystrophies are now Anthropic's first internal drug programs. Anthropic says a drug could enter human trials as early as late 2028 if the candidates hold up. Endpoints News reports that Atlas Venture backed the startup.

Anthropic also published early results from Claude-assisted work with six outside groups: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and the Column Group. The figure Anthropic highlighted is operational: Enveda cut its manufacturing document review time by 89%.

The more technical result came earlier, on Oct. 20, in a research post on scorpion neurotoxins. An internal Claude research model, working largely without human guidance and using 12 protein-design tools, generated 318,484 candidate minibinders against five toxins from scorpions found in Mexico, Brazil, North Africa and the Middle East. It computationally screened 553,052 protein-toxin pairs in 64 hours (Let's Data Science). Adaptyv Bio and Twist Bioscience tested 211 selected designs in the lab, and 17 met strict binding criteria. The best ones bound a Mexican scorpion toxin with single-digit nanomolar affinity.

Anthropic is clear about the limit. The team has not shown that the binders neutralize venom in cells, so it does not claim an antivenom (Let's Data Science). It is releasing all 211 designs and their data.